Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis - PubMed (original) (raw)

Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis

M Detmar et al. J Exp Med. 1994.

Abstract

Psoriatic skin is characterized by microvascular hyperpermeability and angioproliferation, but the mechanisms responsible are unknown. We report here that the hyperplastic epidermis of psoriatic skin expresses strikingly increased amounts of vascular permeability factor (VPF; vascular endothelial growth factor), a selective endothelial cell mitogen that enhances microvascular permeability. Moreover, two VPF receptors, kdr and flt-1, are overexpressed by papillary dermal microvascular endothelial cells. Transforming growth factor alpha (TGF-alpha), a cytokine that is also overexpressed in psoriatic epidermis, induced VPF gene expression by cultured epidermal keratinocytes. VPF secreted by TGF-alpha-stimulated keratinocytes was bioactive, as demonstrated by its mitogenic effect on dermal microvascular endothelial cells in vitro. Together, these findings suggest that TGF-alpha regulates VPF expression in psoriasis by an autocrine mechanism, leading to vascular hyperpermeability and angiogenesis. Similar mechanisms may operate in tumors and in healing skin wounds which also commonly express both VPF and TGF-alpha.

PubMed Disclaimer

Similar articles

• Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin.
  Detmar M, Brown LF, Berse B, Jackman RW, Elicker BM, Dvorak HF, Claffey KP. Detmar M, et al. J Invest Dermatol. 1997 Mar;108(3):263-8. doi: 10.1111/1523-1747.ep12286453. J Invest Dermatol. 1997. PMID: 9036922
• Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions.
  Brown LF, Olbricht SM, Berse B, Jackman RW, Matsueda G, Tognazzi KA, Manseau EJ, Dvorak HF, Van de Water L. Brown LF, et al. J Immunol. 1995 Mar 15;154(6):2801-7. J Immunol. 1995. PMID: 7876550
• Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells.
  Detmar M, Yeo KT, Nagy JA, Van de Water L, Brown LF, Berse B, Elicker BM, Ledbetter S, Dvorak HF. Detmar M, et al. J Invest Dermatol. 1995 Jul;105(1):44-50. doi: 10.1111/1523-1747.ep12312542. J Invest Dermatol. 1995. PMID: 7615975
• Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.
  Dvorak HF, Brown LF, Detmar M, Dvorak AM. Dvorak HF, et al. Am J Pathol. 1995 May;146(5):1029-39. Am J Pathol. 1995. PMID: 7538264 Free PMC article. Review.
• Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine.
  Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, Dvorak HF. Brown LF, et al. EXS. 1997;79:233-69. doi: 10.1007/978-3-0348-9006-9_10. EXS. 1997. PMID: 9002222 Review.

Cited by

• A water-soluble caveolin-1 peptide inhibits psoriasis-like skin inflammation by suppressing cytokine production and angiogenesis.
  Asai C, Takamura N, Watanabe T, Asami M, Ikeda N, Reese CF, Hoffman S, Yamaguchi Y. Asai C, et al. Sci Rep. 2024 Sep 4;14(1):20553. doi: 10.1038/s41598-024-71350-1. Sci Rep. 2024. PMID: 39232048 Free PMC article.
• [Early antiexudative response--OCT monitoring after intravitreal bevacizumab injection].
  Völcker M, Peters S, Inhoffen W, Ziemssen F. Völcker M, et al. Ophthalmologe. 2006 Jun;103(6):476-83. doi: 10.1007/s00347-006-1356-1. Ophthalmologe. 2006. PMID: 16763864 Review. German.
• Vascular endothelial growth factor (VEGF) in autoimmune diseases.
  Carvalho JF, Blank M, Shoenfeld Y. Carvalho JF, et al. J Clin Immunol. 2007 May;27(3):246-56. doi: 10.1007/s10875-007-9083-1. Epub 2007 Mar 6. J Clin Immunol. 2007. PMID: 17340192 Review.
• An important role of lymphatic vessel activation in limiting acute inflammation.
  Huggenberger R, Siddiqui SS, Brander D, Ullmann S, Zimmermann K, Antsiferova M, Werner S, Alitalo K, Detmar M. Huggenberger R, et al. Blood. 2011 Apr 28;117(17):4667-78. doi: 10.1182/blood-2010-10-316356. Epub 2011 Mar 1. Blood. 2011. PMID: 21364190 Free PMC article.
• Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy.
  van Kuijk AW, Tak PP. van Kuijk AW, et al. Curr Rheumatol Rep. 2011 Aug;13(4):353-9. doi: 10.1007/s11926-011-0181-y. Curr Rheumatol Rep. 2011. PMID: 21503693 Free PMC article. Review.

References

1. 1. J Exp Med. 1992 Nov 1;176(5):1375-9 - PubMed
2. 1. Arch Dermatol Res. 1992;284(3):146-9 - PubMed
3. 1. J Clin Invest. 1993 Jan;91(1):153-9 - PubMed
4. 1. Cancer Res. 1993 Jun 15;53(12):2912-8 - PubMed
5. 1. J Clin Invest. 1993 Aug;92(2):671-8 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information